

CLAIMS


1. A compound having the structure:




2,




7,




11,




12,




15,




17,




18,




19,




20,




21,




27,




28,




35,




36,




37,




40,




41,




42,




44,




47i,




48,




67,




68,




76,



77,




79, or




94,

or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, having the structure:




2




7




11




12




27




28




35




36




37




40




41




42




44




47i




48



67




68




76

,




77

,



79

, or




94

,


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, having the structure:




15

,




17

,




18

,




19

,



20

, or




21


,

or a pharmaceutically acceptable salt thereof.


4. The compound of claim 1, having the structure:




2,




7,




36,




37,




40,




41,




42,



68,




79, or




94,

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, having the structure:




7,




40,




41,



42,




79, or



94,

or a pharmaceutically acceptable salt thereof.

6. A compound of Formula (I)



(I),

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is C_4-C_8 alkyl, -S(C_4-C_8 alkyl), C_4-C_8 cycloalkylalkyl, -S(C_4-C_8 cycloalkylalkyl) or C_4-C_8 alkoxy,

wherein R^1 is substituted with one or more substituents, wherein each substituent is fluoro;

R^2 is hydrogen, hydroxyl, C_1-C_3 alkyl, halo, -CF_3, -OCF_3, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

R^3 is hydrogen, hydroxyl, C_1-C_3 alkyl, halo, -CF_3, -OCF_3, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

wherein R^2 and R^3 are not both hydrogen;

R^4 is hydrogen, hydroxyl, C_1-C_3 alkyl, halo, -CF_3, -OCF_3, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

R^5 is hydrogen or C_1-C_3 alkyl;

R^6 is hydrogen or benzyl, wherein the phenyl ring of benzyl is optionally substituted with 1-5 instances of R^{6a};

each R^{6a} is independently selected for each occurrence from the group consisting of hydroxyl, C_1-C_6 alkoxy, C_1-C_6 alkyl, and halogen, or

wherein any two adjacent R^{6a} can be taken together with the atoms on which they are attached to form an optionally substituted C_5-C_7 cycloalkyl or optionally substituted 3-7 membered heterocyclyl; and

wherein when R^1 is $-SCH_2CH_2CH_2CH_2F$ and R^2, R^5, and R^6 are each hydrogen, then at least one of R^3 or R^4 is other than -OMe.

7. The compound of claim 6, wherein:

R^1 is C_4-C_8 alkyl, -S(C_4-C_8 alkyl), or C_4-C_8 alkoxy,

wherein R^1 is substituted with one or more substituents, wherein each substituent is fluoro;

R^2 is hydrogen, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

R^3 is hydrogen, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

wherein R^2 and R^3 are not both hydrogen;

R^4 is hydrogen, C_1-C_3 alkoxy, or -S(C_1-C_3 alkyl);

R^5 is hydrogen or C_1-C_2 alkyl;

R^6 is hydrogen or benzyl, wherein the phenyl ring of benzyl is optionally substituted with 1-5 instances of R^{6a};

each R^{6a} is independently selected for each occurrence from the group consisting of hydroxyl, C_1-C_6 alkoxy, and halogen, or

wherein any two adjacent R^{6a} can be taken together with the atoms on which they are attached to form an optionally substituted 3-7 membered heterocyclyl ring; and

wherein when R^1 is $-SCH_2CH_2CH_2CH_2F$ and R^2, R^5, and R^6 are each hydrogen, then at least one of R^3 or R^4 is other than -OMe.

8. The compound of claim 6, wherein:

R^1 is C_4-C_8 alkyl or -S(C_4-C_8 alkyl),

wherein R^1 is substituted with one or more substituents, wherein each substituent is fluoro;

R^2 is hydrogen or C_1-C_3 alkoxy;

R^3 is hydrogen or C_1-C_3 alkoxy;

wherein R^2 and R^3 are not both hydrogen;

R^4 is hydrogen or C_1-C_3 alkoxy;

R^5 is hydrogen or C_1-C_2 alkyl;

R^6 is hydrogen; and

wherein when R^1 is $-SCH_2CH_2CH_2CH_2F$ and R^2, R^5, and R^6 are each hydrogen, then at least one of R^3 or R^4 is other than -OMe.

9. The compound of claim 6, wherein:

R^1 is C_4-C_8 alkyl or -S(C_4-C_8 alkyl),

wherein R^1 is substituted with one or more substituents, wherein each substituent is fluoro;

R^2 is hydrogen, -OMe, or -OEt;

R^3 is hydrogen, -OMe, or -OEt;

wherein R^2 and R^3 are not both hydrogen;


R^4 is -OMe or -OEt;

R^5 is hydrogen, -Me, or -Et;

R^6 is hydrogen; and

wherein when R^1 is $-SCH_2CH_2CH_2CH_2F$ and R^2, R^5, and R^6 are each hydrogen, then at least one of R^3 or R^4 is other than -OMe.


10. The compound of any one of claims 6-9, wherein the compound is a compound of Formula (I-a):



(I-a),

or a pharmaceutically acceptable salt thereof.


11. The compound of any one of claims 6-9, wherein the compound is a compound of Formula (I-b):



(I-b),

or a pharmaceutically acceptable salt thereof.

12. The compound of any one of claims 6-9, wherein the compound is a compound of Formula (I-c):



(I-c),


or a pharmaceutically acceptable salt thereof.

13. The compound of any one of claims 6-12, wherein R^1 is -S(C_4-C_8 alkyl) substituted with one or more substituents, wherein each substituent is fluoro.


14. The compound of any one of claims 6-12, wherein R^1 is C_4-C_8 alkyl substituted with one or more substituents, wherein each substituent is fluoro.

15. The compound of any one of claims 6-14, wherein R^1 is substituted with one, two, or three substituents, wherein each substituent is fluoro.


16. A compound selected from the group consisting of:




2




27




31




37




42




47




73




74




75




76




77




78




79




80




81




82




83




84




85




86



87




88



89

or a pharmaceutically acceptable salt thereof.

17. A compound of Formula (II):



(II),

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is C_4-C_8 alkyl or -S(C_4-C_8 alkyl),

wherein C_4-C_8 alkyl may be optionally substituted by one or more substituents, each independently selected from the group consisting of hydroxyl, oxo, -CN, -NR^7R^8, C_1-C_6 alkoxy, C_1-C_3 alkyl, phenyl, 5-6 membered heteroaryl, C_3-C_6 cycloalkyl, and 3-6-membered heterocyclyl;

R^3 is selected from the group consisting of hydrogen, halogen, and C_1-C_3 alkyl;

R^5 is hydrogen or C_1-C_3 alkyl;

R^7 and R^8 are independently selected, for each occurrence, from the group consisting of hydrogen and C_1-C_3 alkyl; wherein C_1-C_3 alkyl may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo, and hydroxyl;

or R^7 and R^8, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo, and hydroxyl; and

wherein when R^1 is -$SCH_2CH_2CH_2CH_3$, R^3 and R^5 are not both hydrogen.

18. The compound of claim 17, wherein:

R^1 is C_4-C_8 alkyl or -S(C_4-C_8 alkyl),

wherein C_4-C_8 alkyl may be optionally substituted by one or more substituents, each independently selected from the group consisting of hydroxyl, C_1-C_6 alkoxy, and C_3-C_6 cycloalkyl;

R^3 is selected from the group consisting of hydrogen, halogen, and C_1-C_3 alkyl;

R^5 is hydrogen, Me, or Et; and

wherein when R^1 is -$SCH_2CH_2CH_2CH_3$, R^3 and R^5 are not both hydrogen.

19. The compound of claim 17, wherein:

R^1 is C_4-C_8 alkyl or -S(C_4-C_8 alkyl),

wherein C_4-C_8 alkyl is unsubstituted;

R^3 is selected from the group consisting of hydrogen, halogen, and Me;

R^5 is hydrogen, Me, or Et; and

wherein when R^1 is -$SCH_2CH_2CH_2CH_3$, R^3 and R^5 are not both hydrogen.


20. The compound of any one of claims 6-19, wherein R^5 is hydrogen.

21. The compound of any one of claims 6-19, wherein R^5 is C_1-C_2 alkyl.


22. The compound of any one of claims 6-19, wherein R^5 is Me.

23. The compound of any one of claims 6-19, wherein R^5 is Et.


24. A compound selected from the group consisting of:




4ent1




4ent2




6




7




8




10




11




12




13




14




15




17




18




19




20




21




29




30




36




40




41




43i




44




45




46




47i




48




49




50




51




52




53




54



55



56



or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising the compound of any one of claims 1-24 and a pharmaceutically acceptable carrier.


26. Use of a compound of any one of claims 1-24 in the manufacture of a medicament for the treatment of a psychiatric disease or disorder, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.

27. Use of a compound of any one of claims 1-24 in the manufacture of a medicament for the treatment of headache or headache disorder, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.


28. Use of a compound of any one of claims 1-24 in the manufacture of a medicament for the treatment of an inflammatory disease or disorder, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.

29. Use of a compound of any one of claims 1-24 in the manufacture of a medicament for the treatment of high intraocular pressure, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.


30. Use of a compound selected from the group consisting of:




2




3




4ent1




4ent2




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




33




35




36




37




38




39




40




41




42




43i




44




45




46




47




47i




48




49




50




51




52




53




54




55




56




57




58




59




60




61




63




63i




64




67




67i




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82




83




84




85



86





87




or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a psychiatric disease or disorder, a headache or headache disorder, an inflammatory disease or disorder, or high intraocular pressure, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.

31. The compound of any one of claims 1-24, or a compound selected from the group consisting of:







7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




33




35




36




37




38




39




40




41




42




43i




44




45




46




47




47i




48




49




50




51




52




53




54




55




56




57




58




59




60




61




63




63i




64




67




67i




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82




83




84




85



86



87



or a pharmaceutically acceptable salt thereof, for use in therapy.